March 27-29, 2019 Houston, Texas - 16TH INTERNATIONAL WORKSHOP - MD Anderson Cancer Center
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
16TH INTERNATIONAL WORKSHOP on Multiple Endocrine Neoplasia A Focus on New Concepts and Treatment of Malignant Manifestations March 27-29, 2019 Houston, Texas The University of Texas MD Anderson Cancer Center Dan L. Duncan Building (CPB) Floor 8, Rooms 1-8 1155 Pressler Street Houston, Texas Register at www.men2019.com
Focus
to their practice decisions, performance
In keeping with the spirit of the original MEN workshop, MEN2019
improvement activities, or possible impact
will focus on emerging topics in the genesis and therapy of on patient health status. Participants will also
have the opportunity to comment on any
malignant endocrine tumors associated with multiple endocrine
perceived commercial bias in the presentations
neoplasia. The goal of the workshop will be to provide an outline as well as to identify future educational topics.
for basic and clinical research focused on these malignant
manifestations. The meeting will bring together local and Accreditation/Credit
international experts on multiple endocrine neoplasia to focus on Designation
these subjects. Physicians
The University of Texas MD Anderson Cancer
Center is accredited by the Accreditation
A significiant portion of the meeting will be • Utilize options to treat symptoms of
Council for Continuing Medical Education
spent in workshops centered on emerging excessive hormonal secretion in patients
(ACCME) to provide continuing medical
topics and the development of an international with malignant pheochromocytoma and
education for physicians.
roadmap for future research and clinical trials. paraganglioma (Knowledge, Competence,
Performance); The University of Texas MD Anderson Cancer
The remainder of the meeting will be • Understand menin function and telomere Center designates this live activity for a
composed of large group didactic sessions. biology in pancreatic neuroendocrine maximum of 16.50 AMA PRA Category 1
The University of Texas MD Anderson Cancer tumors (Knowledge); Credits™. Physicians should claim only the
Center is a leader in the development of new • Appreciate the clinical trials available credit commensurate with the extent of their
therapies for cancer. Our goal is to combine for patients with parathyroid cancer and participation in the activity.
the extensive local scientific and clinical talent enroll them appropriately (Knowledge,
at MD Anderson along with international Competence, Performance);
experts to allow focus on emerging topics • Understand basic, clinical, and translational CME Certificates and
including new directions in immunotherapy, genetics with regard to TP53 germline Attendance Verification
emerging concepts in the use of signaling predisposition in ACC patients (Knowledge). Certificates
pathway inhibitors, genetic diagnosis &
therapy and new clinical advances that impact Certificates awarding AMA PRA Category
management of endocrine tumor syndromes. Educational Methods 1 Credit™ or certificates documenting
attendance will be emailed when an individual
• Lecture/Didactic
A specific outcome of this conference will be completes the online CME Verification process.
• Poster Session
a white paper summarizing the goals of this
• Interactive Groups/Breakouts
work.
Presentations – WILL BE AVAILABLE
AFTER THE CONFERENCE
Target Audience
Educational Objectives All of the PowerPoint presentations will
This conference should be of value to clinicians
After attending the conference, participants be posted online after the conference.
(including physicians, nurse practitioners,
should be able to: You will receive an invitation email from
physician assistants and genetic counselors),
• Identify and utilize alternative therapies Study@MD Anderson to create a username
researchers and trainees (students, residents,
to the traditional targeted therapy for the and password to log into Study. If you do not
and fellows).
treatment of medullary thyroid cancer that receive this instructional email by April 8, 2019,
may benefit their patients (Knowledge, please email ambaring@mdanderson.org.
Competence, Performance); Evaluation
• Gain an awareness of modern therapy
A conference evaluation link will be included
for pancreatic neuroendocrine tumors
in the final program. This online survey will
so that the most efficacious therapy may
provide participants with the opportunity to
be delivered (Knowledge, Competence,
comment on the value of the program content
Performance, Patient Outcomes);Deadline for Abstract Submission
is Monday, January 7, 2019.
The Planning Committee invites the
submission of abstracts. The goal is to
provide the audience an opportunity to
collaborate and stimulate discussions
specifically on emerging topics in the
genesis and therapy of malignant endocrine
tumors associated with multiple endocrine
neoplasia.
Authors may submit abstracts of completed Conference Planning International Committee
work, work in progress, or work presented Committee
elsewhere. Albert Beckers, MD, PhD
Robert Gagel, MD (Chair) Professor of Endocrinology
Professor Chu Sart Tilman
Abstract Submission Endocrine Neoplasia and Hormonal Disorders Endocrinology
Liège, Belgium
Instructions: MD Anderson Cancer Center
Abstracts will only be accepted Elizabeth Grubbs, MD (Co-Chair) Jérôme Bertherat, MD, PhD
electronically and should be uploaded to: Associate Professor Head
MEN2019@mdanderson.org Surgical Oncology Center for Rare Adrenal Diseases
MD Anderson Cancer Center Cochin Hospital
Six abstracts will be chosen for an oral Professor of Endocrinology
presentation. The remainder of the selected
Daniel Halperin, MD (Co-Chair) Paris Descartes University
Assistant Professor Paris, France
abstracts will be presented in a poster
Gastrointestinal Medical Oncology
session. MD Anderson Cancer Center Maria Luisa Brandi, MD, PhD
Professor of Endocrinology
The deadline for receipt of abstracts is Steven Waguespack, MD (Co-Chair) University of Florence Medical School
11:59 PM CST on Monday, January 7. Professor Florence, Italy
Notification of acceptance for oral and/or Endocrine Neoplasia and Hormonal Disorders
poster presentations will be acknowledged MD Anderson Cancer Center Friedhelm Raue, MD
Professor of Internal Medicine /
by e-mail by Wednesday, January 23, 2019.
Allison Baring, CMP Endocrinology
CME Conference Planner Medical Faculty University of Heidelberg
CME/Conference Management Endocrine Practice
Abstract Formatting
MD Anderson Cancer Center Heidelberg, Germany
Instructions:
Please indicate in your abstract whether Naifa Busaidy, MD Bruce Robinson, MD, MSc, FRACP
Associate Professor Honorary Professor
you would like to be considered for an
Endocrine Neoplasia and Hormonal Disorders Medicine
oral presentation, a poster or both. 200
MD Anderson Cancer Center Northern Clinical School
word limit. Limit abstracts to one page, Kolling Institute of Medical Research
type in 12-point Times New Roman font, Patricia L. Dahia, MD, PhD The University of Sydney School of Medicine
single spaced with one-inch margins, Associate Professor Sydney, Australia
and left justified. Organize the abstract Department of Medicine and Hematology
into: Background, Methods, Results, and and Medical Oncology Constantine Stratakis, MD, D(Med)Sc
Conclusions. Define all abbreviations. University of Texas Health Science Center at Scientific Director
San Antonio National Institute of Child Health and Human
Include the abstract title, full names, and
San Antonio, Texas Development
institutional affiliations of all authors, and
National Institutes of Health
e-mail address of the corresponding author Mimi Hu, MD Bethesda, Maryland
at the top of the abstract. Underline the Professor
name of the presenting author. Abstracts Endocrine Neoplasia and Hormonal Disorders Raj Thakker, MA MD Cantab, FRCP,
must not contain copyrighted material MD Anderson Cancer Center FRCPath, FmedSci, FRS
unless permission has been obtained by the May Professor of Medicine
Camilo Jimenez, MD University of Oxford
author/publisher.
Professor Oxford, England
Endocrine Neoplasia and Hormonal Disorders
MD Anderson Cancer Center Gerlof D. Valk, MD, PhD
Professor
Nancy Perrier, MD Endocrine Oncology
Professor UMC Utrecht
Surgical Oncology Utrecht, Netherlands
MD Anderson Cancer CenterConference Agenda
T U E S D AY, M A R C H 2 6 3:30 Transcriptional Targeting of OncoGene
Addiction in MTC
5:30 pm Registration and Welcome Reception – Mays West Matthew D. Ringel, MD
Lobby
3:50 Lessons Learned From TCGA and Other Large
A Celebration of the 50th anniversary of screening for Scale Genomics Programs
Hereditary Medullary Thyroid Cancer Kenna Shaw, PhD
4:10 Closing Remarks
W E D N E S D AY, M A R C H 2 7 4:15 pm Adjourn
7:00 am Registration and Continental Breakfast
T H U R S D AY, M A R C H 2 8
8:00 Welcome and Opening Remarks
7:00 am Registration and Continental Breakfast
PANCREATIC NEUROENDOCRINE TUMORS
7:30 Breakfast Talk - Hereditary Gastrointestinal
Neuroendocrine Tumors (optional, non-CME)
8:30 State of the Science in Pancreatic
Sponsored by Lexicon
Neuroendocrine Tumors
Daniel Halperin, MD 8:00 Welcome and Opening Remarks
8:50 Emerging Therapies and Epigenetics
Kate Lines, PhD MALIGNANT PHEOCHROMOCYTOMA AND
PARAGANGLIOMA
9:10 Menin and Telomeres in Pancreatic
Neuroendocrine Tumors
Christopher M. Heaphy, PhD 8:10 State of the Science in Malignant
Pheochromocytoma and Paraganglioma
9:30 Observational Studies of Tumor Growth Eric Baudin, MD, PhD
Samira Sadowski, MD
8:30 Radiopharmaceuticals, Tyrosine Kinase
9:50 Perioperative Clinical Trials Inhibitors and Immunotherapy for Patients
Matthew HG Katz, MD with Malignant Pheochromocytoma and
Paraganglioma
10:10 Poster Preview Presentations Camilo Jimenez, MD
- 3 at 5 minutes each
8:50 Pseudohypoxia as a Therapeutic Target:
10:25 Break/Poster Viewing Lessons from Clusters One and Two
Patricia L. Dahia, MD, PhD
11:10 Plenary Session: Common Failures in Rare
Diseases 9:10 Epigenetic Characteristics of Paraganglioma
Moderator: Steven Sherman, MD Syndrome Type 4
Mercedes Robledo, PhD
12:15 Lunch (provided)- Working Lunch in Workshop
groups 9:30 Enabling Replicative Immortality in
Pheochromocytoma and Paraganglioma
12:30 pm – 2:30 Disease Site Working Groups (choose one) Anne-Paule Gimenez-Roqueplo, MD, PhD
• Medullary Thyroid Cancer
• Parathyroid Cancer 9:50 Break/Poster Viewing
• Pancreatic Neuroendocrine Tumor (PNET)
• Malignant Pheo/PGL 10:00 Plenary Session: Immune Checkpoint
Blockade in Cancer Therapy: New Insights,
2:30 Break Opportunities and Prospects for Cures
James Allison, PhD
MEDULLARY THYROID CANCER 11:00 Poster Preview Presentations
- 3 at 5 minutes each
2:45 Emerging Therapies In MTC
RET Inhibitor LOXO-292 11:15 Break/Poster Viewing
Lori J. Wirth, MD
11:45 Lunch (provided)- Working Lunch in Workshop
RET Inhibitor BLU-667 groups
Mimi I. Hu, MD
Future Trial Development for MTC
Vivek Subbiah, MD12:00 – 2:00 pm Disease Site Working Groups (choose one) 8:25 What is New in Familial Isolated Pituitary
• Medullary Thyroid Cancer Adenoma?
• Parathyroid Cancer Albert Beckers, MD, PhD
• Pancreatic Neuroendocrine Tumor (PNET)
• Malignant Pheo/PGL 8:40 X-LAG: An Update
Constantine Stratakis, MD, DMSci
2:00 Break/Poster Viewing
8:55 Adrenocortical Tumors: Novel Insights into
Pathogenesis of Malignant Adrenocortical
PARATHYROID CANCERS Tumors
Tobias Else, MD
2:15 Genetic Syndromes of PHPT and
Parathyroid Cancer 9:10 Benign Adrenocortical Tumors
Maria-Luisa Brandi, MD Jérôme Bertherat, MD, PhD
2:35 Genetic and Molecular Alterations in 9:25 VHL as a Paradigm for the Simultaneous
Parathyroid Cancer Treatment of Multiple Hereditary Tumors
Andrew Arnold, MD Eric Jonasch, MD
2:55 CDC73 9:40 VHL and Pancreatic NETs: An Update
Electron Kebebew, MD
3:15 The Role of Local Therapies in Parathyroid 10:30 Break/Poster Viewing
Cancer: Surgery and Radiotherapy
Nancy Perrier, MD 10:45 Summary of Working Groups
3:35 Targeted Therapies and Trials in 12:00 pm Adjourn
Parathyroid Cancer
Naifa Busaidy, MD
3:55 Closing Remarks
4:00 pm Adjourn
6:30 pm Dinner at Space Center Houston
F R I D AY, M A R C H 2 9
7:00 am Registration and Continental Breakfast
8:00 Welcome and Opening Remarks
PITUITARY, ADRENAL CORTEX AND
ADRENOCORTICAL TUMORS
8:10 Aggressive Pituitary Tumors: An Update on
Pathologic Features and Genomics
Gérald Raverot, MD, PhD
The University of Texas MD Anderson Agendas are subject to change because we Please let us know what specific
Cancer Center has implemented a process are always striving to improve the quality of topics, issues or questions you wish to
whereby everyone who is in a position your educational experience. MD Anderson see addressed or emphasized in this
to control the content of an educational may substitute faculty with comparable activity. Fax or e-mail CME/Conference
activity must disclose all relevant financial expertise on rare occasions necessitated by Management. All responses will be
relationships with any commercial interest illness, schedule conflicts, and so forth. forwarded to the Program Chairs for
that could potentially affect the information consideration.
presented. MD Anderson also requires Photographing, audio taping and
that all faculty disclose any unlabeled use videotaping are prohibited.
or investigational use (not yet approved
for any purpose) of pharmaceutical The University of Texas MD Anderson
and medical device products. Specific Cancer Center does not endorse the
disclosure will be made to the participants commercial products, equipment, or
prior to the educational activity. services presented by program supporters/
exhibitors.M D A N D E R S O N FA C U LT Y
James Allison, PhD Mimi I. Hu, MD Nancy Perrier, MD
Professor and Chair Professor Professor
Immunology Endocrine Neoplasia and Hormonal Disorders Surgical Oncology
Chief Scientific Advisor ad interim Chief
Vivian L. Smith Distinguished Chair Camilo Jimenez, MD Section of Surgical Endocrinology
Immunology Professor Fellowship Program Director
Director Endocrine Neoplasia and Hormonal Disorders Surgical Endocrinology
Parker Institute for Cancer Immunotherapy Associate Medical Director
(PICI) Eric Jonasch, MD Multidisciplinary Endocrine Center
Executive Director Professor
Immunotherapy Platform Genitourinary Medical Oncology Kenna Shaw, PhD
Deputy Director Executive Director
Matthew HG Katz, MD Institute for Personalized Cancer Therapy
David H. Koch Center for Applied Research of
Associate Professor
Genitourinary Cancers
Vice Chair - Research Vivek Subbiah, MD
Naifa Busaidy, MD Surgical Oncology Associate Professor
Associate Professor Investigational Cancer Therapeutics
Endocrine Neoplasia and Hormonal Disorders
James C. Yao, MD
Daniel Halperin, MD Professor and Chair
Assistant Professor Gastrointestinal Medical Oncology
Gastrointestinal Medical Oncology
G U E S T FA C U LT Y
Andrew Arnold, MD Patricia L. Dahia, MD, PhD Gérald Raverot, MD, PhD
Murray-Heilig Chair in Molecular Medicine Associate Professor Professor of Universities – Hospital Practitioner
Professor of Medicine and Genetics and Department of Medicine and Hematology and Department of Endocrinology and Diabetology
Genome Sciences Medical Oncology CHU Lyon HCL - GH East Hospital Louis Pradel
Chief University of Texas Health Science Center at San Lyon, France
Division of Endocrinology and Metabolism Antonio
Director San Antonio, Texas Matthew D. Ringel, MD
Center for Molecular Oncology and Ralph W. Kurtz Chair and Professor of
Chief Academic Officer Tobias Else, MD Medicine
Carole and Ray Neag Comprehensive Assistant Professor Director
Cancer Center Michigan Medicine Endocrine Oncology Division of Endocrinology, Diabetes, and
Director Rogel Cancer Center Metabolism
Office of Physician-Scientist Career Ann Arbor, Michigan Co-Director, Thyroid Cancer Unit
Development The James- The Ohio State University
Center for Molecular Oncology Anne-Paule Gimenez-Roqueplo, MD, PhD Comprehensive Cancer Center
UConn Health Professor Columbus, Ohio
Farmington, Connecticut Genetics
Georges Pompidou European Hospital Mercedes Robledo, PhD
Eric Baudin, MD, PhD Paris, France Hereditary Endocrine Cancer Group, Group
Professor and Head Leader
Neuroendocrinology Christopher M. Heaphy, PhD Human Cancer Genetics Program
Gustave Roussy Cancer Campus Assistant Professor Spanish National Cancer Research Center
Villejuif, France Pathology and Oncology (CNIO)
The Johns Hopkins University School of Medicine Madrid, Spain
Albert Beckers, MD, PhD Baltimore, Maryland
Professor and Chief Samira Sadowski, MD
Department of Endocrinology Electron Kebebew, MD Endocrine Surgeon
CHU de Liège Professor University Hospitals of Geneva
Domaine Universitaire du Sart-Tilman Chief Geneva, Switzerland
Liège, Belgium Division of General Surgery
Harry A. Oberhelman Jr. and Mark L. Welton Constantine Stratakis, MD, DMSci
Jérôme Bertherat, MD, PhD Professor Scientific Director
Professor Program Leader, Endocrine Oncology Program National Institute of Child Health and Human
Hôpital Cochin Stanford Cancer Center Development
Paris Descartes University Stanford, California National Institutes of Health
Paris, France Bethesda, Maryland
Kate Lines, PhD
Maria Luisa Brandi, MD Postdoctoral Researcher Lori J. Wirth, MD
Professor University of Oxford Medical Director
Endocrinology Churchill Hospital Center for Head and Neck Cancers
University of Florence Medical School Oxford, United Kingdom Massachusetts General Hospital Cancer
Florence, Italy Center
Boston, MassachusettsWe sincerely hope you can join
us for dinner at Space Center
Houston on Thursday, March 28.
Space Center Houston is the Official Visitor Center of NASA
Johnson Space Center, the home of astronaut training,
International Mission Control and human space exploration.
Dinner will be held in the Astronaut Gallery beginning
at 6:30 pm- You will be able to see the ejection suit that
astronaut John Young wore on the first shuttle flight in 1981
along with the T-38 flight suit worn by our second female
astronaut and fallen hero, Judy Resnik. You’ll also have an
opportunity to see a Saturn V rocket; the tallest, heaviest
and most powerful rocket ever brought to operational status
and responsible for launching astronauts to the moon. You
won’t want to miss this unique experience!
Registration if a written request is received on or before • Early hotel reservation is suggested and the
Information
February 15, 2019. No refunds will be granted room block cutoff date is:
after that date. The request for a registration Tuesday, March 5, 2019.
Early registration and a Welcome Reception refund must include the tax identification • The hotel phone number is 713-528-7744
begin at 5:30 pm on Tuesday, March 26. number of the company or institution if • When you make reservations, be sure
On-site registration will begin at 7:00 am on registration was paid by a company or to mention the group name: Multiple
Wednesday, March 27 and the Welcome and institution check. Endocrine Neoplasia 2019 room block to be
Introductions will begin at 8:00 am. Advanced assured of receiving the special meeting rate
registration is encouraged as space and CME/Conference Management reserves the of $165 for a single or double guest room.
materials are limited. right to cancel activities prior to the scheduled Please add 17% Texas state and local taxes.
date, if low enrollment or other circumstances
The deadline for advanced registration is make it necessary. Each registrant will
Friday, February 15, 2019. be notified by mail, e-mail, or the contact Ground Transportation
numbers as given on the registration form. (prices are subject to change and variable
There are three ways to register: In case of activity cancellation, liability of the depending on location of conference)
1. Online at www.mdanderson.org/conferences CME/Conference Management is limited to the
2. Fax to: 713-794-1724 registration fee. CME/Conference Management • Houston is served by two airports, George
3. Mail to: CME/Conference Management will refund the full registration fee. Bush Intercontinental (IAH) and William P.
Unit 1781 Hobby (HOU).
The University of Texas MD CME/Conference Management reserves the • Taxicabs are available at an estimated cost
Anderson Cancer Center right to limit the number of participants in for $50-60, to or from William P. Hobby
P.O. Box 301407 a program and is not responsible for any Airport or George Bush Intercontinental
Houston, TX 77230-1407 expenses incurred by an individual whose Airport.
registration is not confirmed and for whom • Super Shuttle operates a shuttle bus
We accept the following forms of payment: space is not available. between George Bush Intercontinental
• Check (payable through U.S. banks only) Airport and the Wyndham Houston Medical
• Money Order For additional information, please contact Center for $27 one-way and $54 round-trip.
• Credit Cards (MasterCard, VISA, and CME/Conference Management at 713-792-2223 For more information, call 713-523-8888 or
American Express) or toll free at 866-849-5866. toll-free at 800-258-3826 or online at
• Cash (on-site registration only) www.supershuttle.com.
• Super Shuttle operates a shuttle bus
A receipt and confirmation letter will be sent to Special Assistance between William P. Hobby Airport and the
you within ten working days of receipt of your Contact CME/Conference Management at Wyndham Houston Medical Center for
fee. The conference registration fee includes 713-792-2223 or toll-free at 866-849-5866 $24 one-way and $48 round-trip. For more
tuition, final conference agenda, continental if you have any special dietary or ADA information, call 713-523-8888 or toll-free at
breakfasts, breaks, lunch and a welcome accommodation needs. 800-258-3826 or online at www.supershuttle.
reception. Please refer to the registration form com.
for specific information regarding fees.
Accommodations
• A block of rooms has been reserved for
Refund/Cancellation Policy
conference attendees at the Wyndham
The registration fee, minus a $50 Houston – Medical Center located at 6800
administrative handling fee, is refundable South Main Street, Houston, Texas 77030.CONFERENCE REGISTRATION - 176700/30/120473/41
MEN 2019: 16th International Workshop on Multiple Endocrine Neoplasia- A Focus on
New Concepts and Treatment of Malignant Manifestations — March 27-29, 2019
Last Name First MI Highest Degree
Department (include unit no.) Specialty
Institution
MD Anderson Employee ID No. (required for all MDACC employees): Physician
Yes No
Street
City State/Foreign Country/Zip or Mail Code
Daytime Phone (with area code) Cell Phone (with area code) Fax (with area code)
E-mail Address (please print)
Emergency Contact Phone (with area code)
Credit Card Holder Name (First/Last) Charge the following:
VISA MC AMEX
Credit Card Number Expiration Date
Security Code/CVV/CSV Credit Card Holder Billing Address & ZIP Code
MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted
Business Unit Department Fund Group* Fund Fund Type
Authorized Signature REQUIRED for CREDIT CARD or IDT IDT Approver Name (First/Last) please print
THIS IS NOT A SELF-MAILER - Address to:
MEN 2019: 16th International Workshop on Multiple Endocrine Neoplasia-
A Focus on New Concepts and Treatment of Malignant Manifestations
CME/Conference Management – Unit 1781
The University of Texas MD Anderson Cancer Center
PO Box 301407, Houston, TX 77230-1407
or fax to 713-794-1724
Make check or money order payable to:
The University of Texas MD Anderson Cancer Center
Registration Fees
Postmarked before February 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $600
Postmarked after February 15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $700
Students/Fellows/Residents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $200
MD Anderson Faculty/Staff. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $200
MD Anderson Trainees. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $50
Will you be attending the Tuesday evening reception at MD Anderson? Yes No
Space Center Houston Dinner Ticket (evening of March 28, 2019):
(Roundtrip transportation included) ________ x $85/person
Which working group would you like to attend?
(Choose One) Final working group composition and number to be confirmed pending registration interest.
Medullary Thyroid Cancer
PNET
Parathyroid Cancer
Malignant Pheochromocytoma/Paraganglioma
You can also read
